Oxford BioMedica names James Christie head of manufacturing
This article was originally published in Scrip
Executive Summary
Oxford BioMedica, a UK-based gene therapy company, has appointed James Christie to the newly created role of head of manufacturing. Mr Christie, a biopharmaceutical executive with more than 30 years' industry experience, was most recently operations director at BTG. His appointment follows the announcement that Oxford BioMedica is to acquire a manufacturing facility, based in Oxford, from Recipharm Cobra Biologics for £1.9 million (scripintelligence.com, 31 January 2011).